

## Special Issue

# SARS-CoV-2 Serological Studies around the World

### Message from the Guest Editors

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for COVID-19, a severe pneumonia leading to respiratory distress, has now spread around the world with more than 615 million people being infected. During the course of the pandemic, several variants carrying amino acid changes in the entire genome of SARS-CoV-2 emerged worldwide. The emergence of these variants was often accompanied by a loss of effectiveness of immune efficiency, induced by primary infection, vaccination or therapeutic treatments. The need for serological investigation to analyze the antibody responses, titer and duration elicited by primary infection or vaccination against the circulating variants will greatly help the identification of the populations at risk of re-infection and will help monitor the efficacy of COVID-19 vaccines, thus, accelerating the public health policy decision. For this Special Issue, both reviews and research articles describing the SARS-CoV-2 sero-epidemiology using robust system or gold standard tools will be welcome.

---

### Guest Editors

Dr. Julien Mélade  
Dr. Paola Mariela Saba Villarroel  
Dr. François Meurens

---

### Deadline for manuscript submissions

closed (20 October 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/145198](https://mdpi.com/si/145198)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).